My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

31.34 -0.63 (-1.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright
Markets closed in the green on Tuesday, undeterred by the looming U.S. government shutdown. Pfizer surged nearly 7% on a political deal, while CoreWeave soared after signing a multibillion-dollar AI... 
Via Chartmill
Topics Artificial Intelligence
Here are the top movers in Tuesday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
AnaptysBio Charts Path To Split Into Two Public Companies By 2026
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level
Via Stocktwits
Why Is Eli Lilly’s Stock Slipping Premarket?
Via Stocktwits
Analyst Expectations For AnaptysBio's Future
 
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Tuesday's session: gap up and gap down stocks
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million. 
Via Benzinga
Analyst Expectations For AnaptysBio's Future
 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
 
Via Benzinga
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in September Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
Via The Motley Fool
Topics Intellectual Property
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
 
Via Benzinga
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering
The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects. 
Via Stocktwits
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
From AnaptysBio, Inc.
Via GlobeNewswire
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For AnaptysBio
 
Via Benzinga
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Gains 1%; US Composite PMI Surges In March
 
Via Benzinga
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.